Drug intelligence / Profile preview

huqizhengxiao formula

Development stage: Unknown
Lead developer: Beijing YouAn Hospital
Administration: Oral

Overview

Huqizhengxiao (HQZX) is a traditional Chinese medicine (TCM) decoction composed of ten herbs, primarily investigated for its antitumor effects in hepatocellular carcinoma (HCC). It appears to exert its therapeutic effects by inhibiting tumor cell proliferation and inducing apoptosis. Mechanistically, HQZX has been shown to reduce telomerase activity and downregulate the phosphorylation of signaling molecules in the ERK and STAT3 pathways. It is currently being evaluated in clinical trials, such as ChiCTR2400080963, as a combination therapy with Western medicine for patients with hepatitis B-related hepatocellular carcinoma and liver cirrhosis.

Other names: Huqizhengxiao decoctionHQZX decoctionHuqizhengxiao formula

Targets

TERT (Telomerase)STAT3 (Signal Transducer and Activator of Transcription 3)ERK

Beyond the preview

Go deeper on huqizhengxiao formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on huqizhengxiao formula.

Explore the full profile